Markets Expand for Single-Use Bioreactors
Biobags Offer Advantages Over Fixed-Tank Systems
The Challenges of Harmonizing Biomarker Data
Why Trial Success Depends on It
Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
Reading miRNAs for Clinical Meaning
Single miRNAs Don’t Say Much, but They May Become Eloquent Biomarkers if We Take Their Testimony in Context
Courtenay C. Brinckerhoff ([email protected]) is a partner, chair of IP Law & Practice, and member of the Chemical, Biotechnology & Pharmaceutical practice of Foley & Lardner.
More GEN Content From This Contributor:
- Columns: KSR: A Bump in the Road for Biotech?
- Columns: Protecting Inventions in the U.S. and Europe
- Columns: Court Blocks PTO-Initiated Patent Reform
- Columns: Enforceability of Patent Licenses Under Fire
- Columns: Written Descriptions: How Much Is Enough?
- Columns: Court Ruling Could Lengthen Patent Term
- GEN Exclusives: Court Confirms “Separate” Written Description Requirement
- Columns: What Biotech Needs to Know about <em>Bilski</em>
- Columns: Patenting Personalized Medicine Methods
- Columns: Inventor Rights Not Affected by Bayh-Dole
- Columns: Is the USPTO Playing the Race Card?
- Columns: A Practical Guide to Patent Reform